SER (Serina Therapeutics) Operating Margin %: 0.00% (As of Mar. 2026)


SER Serina Therapeutics Inc SER
12 GF Score
Price $1.97
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Operating Margin %?

Serina Therapeutics SER +8.84% 12 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Serina Therapeutics ranks worse than 106157.01% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Serina Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-6.28 Mil. Serina Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Serina Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Serina Therapeutics's Operating Margin % or its related term are showing as below:


SER's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.83
* Ranked among companies with meaningful Operating Margin % only.

Serina Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Serina Therapeutics's Operating Income for the three months ended in Mar. 2026 was $-6.28 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-24.44 Mil.


Serina Therapeutics  (AMEX:SER) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Serina Therapeutics Operating Margin % Related Terms


Serina Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Operating Margin % Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
-53.70 -454.00 -104.30 0.00 0.00

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SER vs NRSN, IGC, PVCT: Operating Margin % Comparison

For the Biotechnology subindustry, Serina Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Operating Margin % falls into.


SER
12GF Score
Serina Therapeutics Inc SER
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Serina Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-24.022 / 0
= %

Serina Therapeutics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-6.28 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Serina Therapeutics (SER) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry.
Is Serina Therapeutics' Operating Margin % too high?
Serina Therapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Serina Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Operating Margin % compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #999999 out of 942 companies for Operating Margin %. This places Serina Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Serina Therapeutics (SER), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.97
Price